← Leaderboards
Fabin Dang
Case Western Reserve University
$837,766
Attributed
$837,766
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $249K · FY2021–25$250K$187.5K$125K$62.5K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$837,766 · 2
By mechanism
R00$497,998 · 1
K99$339,768 · 1
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- Derek W Abbott$15,447,395
- Theresa Torres Pizarro$21,932,219
- Goutham Narla$7,540,888
- Peter J. Harte$11,964,000
- James W Jacobberger$5,865,800
Others in their field
Other Emerging Leaders on “Adaptor Signaling Protein”
- Tomohiro Nakamura · Scripps Research Institute, The$3,512,996
- Alexandra M. Deaconescu · Brown University$3,268,438
- Eunhee Choi · Columbia University Health Sciences$3,242,300
- Melike Lakadamyali · University Of Pennsylvania$2,935,693
- Patrycja Marta Dubielecka-Szczerba · Rhode Island Hospital$2,858,388
- Princess Izevbua Imoukhuede · Washington University$2,706,238
Research focus
Adaptor Signaling ProteinAnaphase-Promoting ComplexAnaphaseBreast Cancer TherapyBreast TumorigenesisCancer Stem CellBreast Cancer CellCdk4 GeneCell Culture TechniquesCell CycleCell Cycle ArrestCell Cycle ProgressionCell Cycle ProteinsCell Cycle RegulationCancer TherapyCell ProliferationCellsComplexCouplesCyclin D1DesignEmploymentExhibitsG1 Phase
Grant awards (4)
Novel regulation of the CDK4/Cdh1/Pin1 signaling axis for targeted breast cancer therapies$248,999
R00 · FY2025 · CA · contact PI
Novel regulation of the CDK4/Cdh1/Pin1 signaling axis for targeted breast cancer therapies$248,999
R00 · FY2024 · CA · contact PI
Novel regulation of the CDK4/Cdh1/Pin1 signaling axis for targeted breast cancer therapies$169,884
K99 · FY2022 · CA · contact PI
Novel regulation of the CDK4/Cdh1/Pin1 signaling axis for targeted breast cancer therapies$169,884
K99 · FY2021 · CA · contact PI